Invetech & MeMed win 2026 Good Design Award Gold for MeMed Key™

Award recognizes innovation, design excellence, and impact in Engineering Design

SAN DIEGO, Oct. 9, 2026 /PRNewswire/ -- Invetech, a product realization company that designs, engineers and manufactures fully customizable platforms, announced that its work on the MeMed Key™ has been recognized with a 2026 Gold Good Design Award in the Engineering Design category. 

The MeMed Key™ is a cutting-edge, compact immunoassay platform designed to help address a critical challenge in clinical care: distinguishing between bacterial and viral infections rapidly enough to support timely treatment decisions. The compact, automated platform translates a complex benchtop assay into a practical diagnostic system designed for use closer to the point of need.

"Receiving the Gold Good Design Award is a meaningful milestone for the MeMed Key™. It recognizes our vision of bringing advanced diagnostic technology into clinical practice in a way that is both innovative and intuitive," said Eran Eden, CEO and Co-founder of MeMed. 

The collaboration brought together MeMed's expertise in host-response diagnostics with Invetech's experience in product development and commercialization. Invetech provided end-to-end engineering and manufacturing expertise, including instrument and cartridge design, software, firmware and electronics development, systems engineering, regulatory and safety testing, manufacturing transfer, and production process validation to support commercialization of the MeMed Key™. We would also like to salute frog design for a great collaboration on industrial design and human factors engineering. These capabilities helped accelerate the commercialization of MeMed Key™ and translate a laboratory assay into a practical clinical diagnostic platform. 

The award recognizes the strength of this shared approach: combining scientific ambition, engineering rigor, human-centered design, and manufacturing readiness to create a compact platform that can support more informed clinical decisions.

"We are incredibly proud to receive this award. It recognizes the technical mastery, deep knowledge and dedication behind our work, as well as the strength of the exceptional team that makes it possible. This achievement also reflects the great collaboration with MeMed, whose partnership has been instrumental throughout the journey. We are very proud of what we have accomplished together," said Andreas Knaack, CEO & President at Invetech.

The Good Design Awards Jury noted: "The Jury recognizes MeMed Key™ as a technically sophisticated and highly resolved diagnostic platform that successfully translates complex laboratory testing into a compact point-of-need device. The project demonstrates strong engineering integration and addresses an important global healthcare challenge relating to antimicrobial resistance and diagnostic speed. The Jury was impressed by the thoughtful systems integration, workflow simplification and careful consideration of clinical usability, noting the compelling compact form factor and accessibility of the platform with clear potential to improve responsiveness and decentralization of diagnostic testing. The Jury commends the team on delivering a commercially mature approach to point-of-care diagnostics with substantial impact for general practitioners and patients alike." 

The Good Design Awards are among the most respected international design awards. Each entry is evaluated by a panel of more than 80 international Jurors against three core criteria: Good Design, Design Innovation, and Design Impact. The Gold Winner accolade is awarded to a limited number of top-scoring projects in each category, recognizing excellence across good design, design innovation, and design impact. 

For more information, visit: MeMed Key - Good Design 

About Invetech 

For 40 years, Invetech has partnered with leaders in diagnostics, life sciences, and cell and gene therapy to co-create breakthrough solutions that transform ideas into market-ready technologies and therapies. Whether transitioning from early process development to commercial-scale manufacturing or optimizing complex workflows, our team combines proven technologies, scientific insight and engineering excellence to deliver tailored solutions. Together with our clients, we are advancing healthcare.

To learn more about Invetech: visit https://www.invetechgroup.com/

About MeMed 

MeMed translates the immune system's signals into insights that guide care for patients with acute infections. Its FDA-cleared MeMed BV® test distinguishes bacterial from viral infections in 15 minutes. MeMed BV Flex™, designed for capillary blood testing, and MeMed Severity™, designed to predict severe outcomes in acute infections, have received FDA Breakthrough Device Designation. Both are investigational and have not been cleared for sale.

To learn more about MeMed, visit www.me-med.com.

Contact Emily Ellinger 
Marketing & Communications Manager, Invetech 
[email protected] 

SOURCE Invetech